Evidence map›Paper›PMID 37068159›Full record

ArticleOncotarget2023

Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study.

Ellery Altshuler, Raymond Richhart, William King, Mahmoud Aryan, Akash Mathavan, Akshay Mathavan, Keegan Hones, Daniel F Leach, Logan Pucci, Joshua Riklan and 8 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Ellery AltshulerDepartment of Internal Medicine, University of Florida, Gainesville, FL 32610, USA.
Raymond RichhartDepartment of Internal Medicine, University of Florida, Gainesville, FL 32610, USA.
William KingDepartment of Internal Medicine, University of Florida, Gainesville, FL 32610, USA.
Mahmoud AryanDepartment of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Akash MathavanUniversity of Florida College of Medicine, Gainesville, FL 32610, USA.
Akshay MathavanUniversity of Florida College of Medicine, Gainesville, FL 32610, USA.
Keegan HonesUniversity of Florida College of Medicine, Gainesville, FL 32610, USA.
Daniel F LeachUniversity of Florida College of Medicine, Gainesville, FL 32610, USA.
Logan PucciDepartment of Internal Medicine, University of Florida, Gainesville, FL 32610, USA.
Joshua RiklanDepartment of Internal Medicine, University of Florida, Gainesville, FL 32610, USA.
Pat HaleyDepartment of Internal Medicine, University of Florida, Gainesville, FL 32610, USA.
Ilyas SahinDivision of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL 32610, USA.
Brian RamnaraignDivision of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL 32610, USA.
Sherise RogersDivision of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL 32610, USA.
Ibrahim NassourDivision of Surgical Oncology, Department of Surgery, University of Florida, Gainesville, FL 32610, USA.
Steven HughesDivision of Surgical Oncology, Department of Surgery, University of Florida, Gainesville, FL 32610, USA.
Thomas J GeorgeDivision of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL 32610, USA.
Jesus FabregasDivision of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL 32610, USA.
University of Florida · USUniversity of Florida Health · USUniversity of Alabama at Birmingham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDuodenal adenocarcinoma (DA) is a rare malignancy without validated tumor markers. In practice, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) are often used in the management of DA, though their prognostic value is unknown. MATERIALS AND

methodsA single-institution retrospective review included patients diagnosed with biopsy-confirmed adenocarcinoma of the duodenum between 2006 and 2021. Peri-ampullary tumors were excluded. Levels of CA 19-9 and CEA were collected as continuous variables and were analyzed as binary variables: normal vs. high, using the maximum normal value as a cut-off (normal Ca 19-9 <35 U/ml; CEA <3 ng/ml). Survival analysis was conducted using Kaplan Meier curves, log-rank test and Cox proportional hazards model.

resultsThere were 68 patients included in the final analysis. Median age was 67 years old and median follow-up time was 22.2 months. CA 19-9 and CEA were elevated in 36.8% and 48.5% of patients, respectively. A concomitant elevation of both tumor markers was associated with worsened OS (HR 2.140, 95% CI: 1.114-4.112;

conclusionsIn summary, CA 19-9 and, to a lesser extent, CEA, show promise as prognostic markers in DA. Larger studies are needed to validate their use and to evaluate their performance as markers of recurrence.

Indexed as

AdenocarcinomaDuodenal NeoplasmsAgedBiomarkers, TumorCA-125 AntigenCA-19-9 AntigenCarbohydratesCarcinoembryonic AntigenCohort StudiesHumansPrognosisRetrospective StudiesBiomarkers, TumorCA-125 AntigenCA-19-9 AntigenCarbohydratesCarcinoembryonic AntigenCA 19-9carbohydrate antigencarcinoembrionic antigenCEAduodenal adenocarcinoma

Identifiers

PMID37068159
PMCPMC10109526
OpenAlexW4365814481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.